Pages: « Back 1 2 3 4 5 Next » 


STEM CELL COLLECTION PROGRAM


Following the lead of similar programs underway in Western Europe and in Great Britain, the NCLF recently launched a breakthrough program to promote and support the "stem cell" treatment protocol for leukemia and other cancers and serious illnesses. The stem cell treatment protocol is universally acknowledged in the medical community as the best current hope for eliminating the scourge of leukemia.

NCLF's network of doctors, hospitals, treatment centers and labs will facilitate the harvesting, testing, freezing and storing of stem cells drawn from umbilical cords after birth. These cells, derived from what was formerly medical waste, carry the same core blood elements once available only through bone marrow transplantation, and offer unprecedented hope for sufferers.

Marleni Alonzo is just one of our SUCCESS STORIES.

The Stem Cell Protocol

Pioneered in Europe, and proven in initial studies to be as much as 80 percent effective, the protocol uses stem cells in what is called "hematopoietic reconstitution". In this process the diseased marrow of the leukemia patient is reconstituted with healthy cells, bypassing the need for a matching adult bone marrow donor.
 
This new protocol offers unparalleled potential for alleviating the suffering of the thousands of children and adults who must live every day with the pain of treatment, and the uncertainty of the prospects of a bone marrow transplant.

Stem Cell Banking

The NCLF is currently banking stem cells in cryo-preservation banks in liquid nitrogen at 200 degrees below zero Celsius. Each tube is marked with the donor's name and is bar-coded.

NCLF has two stem cell banking programs: One is for Designated blood cells (for a family's own use if the need arises) and the other is for Non-Designated blood cells (if a family releases its cells for use by anyone in need).

Go to our STEM COLLECTION FORM.

The NCLF Executive Medical Board

The new Executive Medical Board will supplement the Foundation's Medical Advisory Board, which has supported the Foundation since its inception.

The Foundation will continue to work with the national registry, and will continue to encourage donor registration and to expedite conventional therapy until the new treatment is universally available to all patients nationwide.

Pages: « Back 1 2 3 4 5 Next » 
 
:: HOME:: CONTACT US:: LINKS©2008 NCLF